长沙晚报掌上长沙7月10日讯 据《中国企业家》杂志消息被“中间商赚差价”的故事,在创新药行业再次上演。6月2日,美国药企BMS与德国药企BNT宣布达成战略合作:双方将共同开发双抗药物BNT327,交易总金额高达90亿美元。两家国外药企的交易,却在国内创新药圈引发震动。因为这款被交易的药物,实则是BNT从中国药企普米斯生物手中“收来”的。2023年11月,成立仅5年的普米斯生物与BNT达成首笔授权:...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.